Calcpeg
ChemaztechSynthèse de Lipides Bioactifs : publications de l’équipe/Brevets
Voir en ligne : Publications à jour
Depuis 2004 et/ou les plus significatives
Journaux à comité de lecture
1- « An Overview on Isoprostane Research : from Chemistry to Clinical Medicine. » LJ ROBERTS II, T. DURAND, Chem. Phys Lipids 128, 1-2 (2004).
2- « Total Syntheses of Iso- and Neuroprostanes : New Insight in Lipid Chemistry. » T. DURAND, A. GUY, O. HENRY, A. ROLAND, S. BERNAD, J-P. VIDAL, J-C ROSSI, Chem. Phys Lipids 128, 15-33 (2004).
3- « Total Syntheses of the Eight Diastereoisomers of the Syn-Anti-Syn Phytoprostanes F1 Types I an II. » S. EL FANGOUR, A. GUY, V. DESPRES, J-P. VIDAL, J-C ROSSI, T. DURAND, J. Org. Chem 69, 2498-2503 (2004).
4- « Synthesis of a photoactivatable potential inhibitor of the anandamide re-uptake » L. BALAS, M. HELLAL, J-C. ROSSI, T. DURAND, Nat Product Res. 19, 419-423 (2005).
5- « Different pharmacological profile of two close related ester endocannabionoid analogs » M. BOBROV, N. GRETSKAYA, O. PAYET, V. BEZUGLOV, T. DURAND, L. MAURIN, F. TOUREL, O. ADJALI, M. RINALDI-CARMONA, A. MULLER, Life Sciences 2005, 77, 1425-1440
6- « B1-phytoprostanes trigger plant defense and detoxification responses. » C. LOEFFLER, S. BERGER, A. GUY, T. DURAND, G. BRINGMANN, U VON RAD, J. DURNER, M.J. MUELLER, Plant Physiol. 137, 328-340 (2005).
7- « A Flexible Synthesis of the Phytoprostanes B1 Types I an II », S. EL FANGOUR, A. GUY, J-P. VIDAL, J-C ROSSI, T. DURAND, J. Org. Chem 70, 989-997 (2005).
8- « Isoprostanes 15-F2t-IsoP and 5-F2t-IsoP are not triggers of myocardial preconditioning. » C. ARNAUD, J-L. CRACOWSKI, A. HAKIM, T. DURAND, A. GUY, D. GODIN-RIBUOT, G. BESSARD, C. RIBUOT, Clin. Ex. Pharmacol. P. 32, 350-354 (2005).
9- « Enzymatic kinetic resolution of a functionalized 4-hydroxy-cyclopentenone : Synthesis of the key intermediates in the total synthesis of Isoprostanes. » E. PINOT, A. GUY, A-L. GUYON, J-C. ROSSI, T. DURAND, Tetrahedron Asymmetry. 16, 1893-1895(2005).
10- « Les Isoprostanes, Biomarqueurs de Peroxydation Lipidique chez l’Homme : Partie 1 : Nomenclature et Synthèse », T. DURAND, J-L. CRACOWSKI, O. BERDEAUX, Pathol. Biol. 53, 349-355 (2005).
11- « Les Isoprostanes, Biomarqueurs de Peroxydation Lipidique chez l’Homme : Partie 2 : Méthodes de Quantification », O. BERDEAUX, O. SCRUEL, T. DURAND, J-L. CRACOWSKI, Pathol. Biol. 53, 356-363, (2005).
12- « Les Isoprostanes, Biomarqueurs de Peroxydation Lipidique chez l’Homme : Partie 3 : Biomarqueurs et Médiateurs en Physiologie et Pathologie Vasculaire. » J-L. CRACOWSKI, O. BERDEAUX, T. DURAND, Pathol. Biol.53, 364-368 (2005).
13- [1] « Synthesis of a potential photoactivatable anandamide analog », L. Balas, M. G. Cascio, V. Di Marzo and T. Durand, Bioorg Med Chem Lett 2006, 16, 3765-3768.
[14] « F2-Isoprostanes : Review of Analytical Methods », O. Berdeaux, O. Scruel, J.-L. Cracowski and T. Durand, Current Pharmaceutical Analysis 2006, 2, 69-78.
[15] « Cardiovascular pharmacology and physiology of the isoprostanes », J. L. Cracowski and T. Durand, Fundam Clin Pharmacol 2006, 20, 417-427.
[16] « Asymmetric conformational changes in a GPCR dimer controlled by G-proteins », M. Damian, A. Martin, D. Mesnier, J. P. Pin and J. L. Baneres, Embo J 2006, 25, 5693-5702.
[17] « Impact of diabetic polyneuropathy and cardiovascular autonomic neuropathy on the excretion of urinary 8-epi-PGF2alpha and its metabolites (2, 3-dinor and 2, 3-dinor-5, 6-dihydro) », J. Nourooz-Zadeh, C. G. Sohr, T. Durand and D. Ziegler, Free Radic Res 2006, 40, 723-729.
[18] « Development of the first potential covalent inhibitors of anandamide cellular uptake », A. Schiano Moriello, L. Balas, A. Ligresti, M. G. Cascio, T. Durand, E. Morera, G. Ortar and V. Di Marzo, J Med Chem 2006, 49, 2320-2332.
[19] « Potent antimalarial activity of 2-aminopyridinium salts, amidines, and guanidines », M. Calas, M. Ouattara, G. Piquet, Z. Ziora, Y. Bordat, M. L. Ancelin, R. Escale and H. Vial, J Med Chem 2007, 50, 6307-6315.
[20] « Ibogaine and noribogaine : structural analysis and stability studies. Use of LC-MS to determine alkaloid contents of the root bark of Tabernanthe iboga », V. Kontrimaviciute, O. Mathieu, L. Balas, R. Escale, J. P. Blayac and F. M. M. Bressolle, Journal of Liquid Chromatography & Related Technologies 2007, 30, 1077-1092.
[21] « Pharmacological actions of isoprostane metabolites and phytoprostanes in human and bovine pulmonary smooth muscles », C. Liu, T. Tazzeo, A. Guy, T. Durand and L. J. Janssen, Prostaglandins Leukot Essent Fatty Acids 2007, 76, 57-64.
[22] « Synthesis and antimalarial activity of new 1,12-bis(N,N’-acetamidinyl)dodecane derivatives », M. Ouattara, S. Wein, M. Calas, Y. Vo-Hoang, H. Vial and R. Escale, Bioorg. Med. Chem. Lett. 2007, 17, 593-596.
[23] « Beyond prostaglandins - Chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids », U. Jahn, J. M. Galano and T. Durand, Angewandte Chemie-International Edition 2008, 47, 5894-5955.
[24] « Quantification of urinary F2-isoprostanes with 4(RS)-F4t-neuroprostane as an internal standard using gas chromatography-mass spectrometry Application to polytraumatized patients », E. Mas, F. Michel, A. Guy, V. Bultel, Y. Falquet, P. Chardon, J. C. Rossi, J. P. Cristol and T. Durand, J Chromatogr B Analyt Technol Biomed Life Sci 2008, 872, 133-140.
[25] « Stereocontrolled Access to Isoprostanes via a Bicyclo[3.3.0]octene Framework », C. Oger, Y. Brinkmann, S. Bouazzaoui, T. Durand and J. M. Galano, Organic Letters 2008, 10, 5087-5090.
[26] « Total Synthesis of the Four Enantiomerically Pure Diasteroisomers of the Phytoprostanes E(1)Type II and of the 15-E(2t)-Isoprostanes », E. Pinot, A. Guy, A. Fournial, L. Balas, J. C. Rossi and T. Durand, J Org Chem 2008, 73, 3063-3069.
[27] « Total synthesis of 4-F3t-neuroprostane and its 4-epimer », A.-L. Auvinet, B. Eignerová, A. Guy, M. Kotora and T. Durand, Tetrahedron Lett. 2009, 50, 1498-1500.
[28] « Total synthesis of photoactivatable or fluorescent anandamide probes : novel bioactive compounds with angiogenic activity », L. Balas, T. Durand, S. Saha, I. Johnson and S. Mukhopadhyay, J. Med. Chem. 2009, 52, 1005-1017.
[29] « Flaxseed oil supplementation increases plasma f1-phytoprostanes in healthy men », A. E. Barden, K. D. Croft, T. Durand, A. Guy, M. J. Mueller and T. A. Mori, J Nutr 2009, 139, 1890-1895.
[30] « N-substituted bis-C-alkyloxadiazolones as dual effectors : efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials », M. Degardin, S. Wein, T. Durand, R. Escale, H. Vial and Y. Vo-Hoang, Bioorg Med Chem Lett 2009, 19, 5233-5236.
[31] « New Bioactive Oxylipins Formed by Non-Enzymatic Free-Radical-Catalyzed Pathways : the Phytoprostanes », T. Durand, V. Bultel-Poncé, A. Guy, S. Berger, M. J. Mueller and J. M. Galano, Lipids 2009, 44, 875-888.
[32] « Measurement of urinary F(2)-isoprostanes by gas chromatographymass spectrometry is confounded by interfering substances », E. Mas, A. Barden, T. Durand, J. M. Galano, K. D. Croft and T. A. Mori, Free Radic Res 2009.
[33] « Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents », M. Ouattara, S. Wein, S. Denoyelle, S. Ortial, T. Durand, R. Escale, H. Vial and Y. Vo-Hoang, Bioorg. Med. Chem. Lett. 2009, 19, 624-626.
[34] « Reverse-benzamidine antimalarial agents : Design, synthesis, and biological evaluation », O. Berger, S. Wein, J. F. Duckert, M. Maynadier, S. E. Fangour, R. Escale, T. Durand, H. Vial and Y. Vo-Hoang, Bioorg Med Chem Lett 2010, 20, 5815-5817.
[35] « Total Synthesis of 15-D-2t- and 15-epi-15-E-2t-Isoprostanes », Y. Brinkmann, C. Oger, A. Guy, T. Durand and J. M. Galano, J. Org. Chem. 2010, 75, 2411-2414.
[36] « A cautionary note on the correct structure assignment of phytoprostanes and the emergence of a new prostane ring system », U. Jahn, J. M. Galano and T. Durand, Prostaglandins Leukotrienes and Essential Fatty Acids 2010, 82, 83-86.
[37] « Measurement of urinary F-2-isoprostanes by gas chromatography-mass spectrometry is confounded by interfering substances », E. Mas, A. Barden, T. Durand, J. M. Galano, K. D. Croft and T. A. Mori, Free Radic. Res. 2010, 44, 191-198.
[38] « The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes : Results from two placebo-controlled interventions », E. Mas, R. J. Woodman, V. Burke, I. B. Puddey, L. J. Beilin, T. Durand and T. A. Mori, Free Radic Res 2010, 44, 983-990.
[39] « The Handy Use of Brown’s P2-Ni Catalyst for a Skipped Diyne Deuteration : Application to the Synthesis of a [D(4)]-Labeled F(4t)-Neuroprostane », C. Oger, V. Bultel-Ponce, A. Guy, L. Balas, J. C. Rossi, T. Durand and J. M. Galano, Chemistry, a european journal 2010, 16, 13976-13980.
[40] « New Insight in Lipase-Catalyzed Regioselective Monoacetylation of Unsymmetrical 1,5-Primary Diols », C. Oger, Z. Marton, Y. Brinkmann, V. Bultel-Poncé, T. Durand, M. Graber and J. M. Galano, J. Org. Chem. 2010, 75, 1892-1897.
[41] « Synthesis and Evaluation of Hybrid Bis-cationic Salts as Antimalarial Drugs », S. Ortial, S. Denoyelle, S. Wein, O. Berger, T. Durand, R. Escale, A. Pellet, H. Vial and Y. Vo-Hoang, Chemmedchem 2010, 5, 52-55.
[42] « Rapid access to structured triacylglycerols acylated with n-3 polyunsaturated fatty acids for nutritional applications », E. Vaique, A. Guy, L. Couedelo, I. Gosse, T. Durand, M. Cansell and S. Pinet, Tetrahedron 2010, 66, 8872-8879.
[43] « Isoprostanes and phytoprostanes : Bioactive lipids », T. Durand, V. Bultel-Ponce, A. Guy, S. El Fangour, J. C. Rossi and J. M. Galano, Biochimie 2011, 93, 52-60.
[44] « Symmetrical choline-derived dications display strong anti-kinetoplastid activity », H. M. Ibrahim, M. I. Al-Salabi, N. El Sabbagh, N. B. Quashie, A. A. Alkhaldi, R. Escale, T. K. Smith, H. J. Vial and H. P. de Koning, J Antimicrob Chemother 2011, 66, 111-125.
[45] « Pharmacokinetic properties and metabolism of a new potent antimalarial N-alkylamidine compound, M64, and its corresponding bioprecursors », D. Margout, F. Gattacceca, G. Moarbess, S. Wein, C. Tran van Ba, S. Le Pape, O. Berger, R. Escale, H. J. Vial and F. M. Bressolle, Eur J Pharm Sci 2011, 42, 81-90.
Actes de colloques (avec comité de lecture)
1- « General Review on the Synthesis of Isoprostanes and Analogs », T. DURAND, A. GUY, J-P. VIDAL, J-C. ROSSI, Prostaglandins Leukot Essent Fatty Acids 71, 33-35 (2004)
2- « Total Synthesis of Iso-and Neuroprostanes : biomarkers of lipid peroxidation. », A. GUY, A. FOURNIAL, S. BERNAD, O. HENRY, J-P. VIDAL, J-C. ROSSI, T. DURAND, Prostaglandins Leukot Essent Fatty Acids 71, 49-50 (2004).
3- « Total Synthesis of Phytoprostanes F1 type I and II », S. EL FANGOUR, A. GUY, V. DESPRES, J-P. VIDAL, J-C. ROSSI, T. DURAND, Prostaglandins Leukot Essent Fatty Acids 71, 50-51 (2004).
4- « Total Synthesis of Phytoprostanes B1 », S. EL FANGOUR, A. GUY, J-P. VIDAL, J-C. ROSSI, T. DURAND, Prostaglandins Leukot Essent Fatty Acids 71, 51-52 (2004).
Articles généraux, revues
Beyond prostaglandins—chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids, U. Jahn, J. M. Galano, T. Durand, Angew. Chem. Int. Ed. 47 (2008) 5894-955.
« Radical Cyclization of highly functionalized 1-susbtituted-2,4-dihydroxylated-hex-5-enyl radicals : Useful tools for the synthesis of Iso-and Neuroprostanes. » T. DURAND, A. GUY, O. HENRY, A. ROLAND, S. BERNAD, J-P. VIDAL AND J-C ROSSI, Recent Res. Devel. Organic Chem., 6 (Part II), 521-530 (2002).
Brevets
H.J. VIAL, M. CALAS, R. ESCALE, V. VIDAL-SAILHAN, F. BRESSOLLE, M.L. ANCELIN, Composés à activités antiparasitaires et médicaments les contenant. Applied by CNRS, N° 0209156, July, 18, 2002, PCT/FR03/02283, July, 18, 2003, WO 2004/009068. Patent and know how in the field of human health have been licenced to Sanofi Synthelabo, Dec 2002.
Voir en ligne : Publications à jour
